多发性骨髓瘤
癌症研究
癌症干细胞
CD38
癌症
人口
干细胞
医学
骨髓
癌细胞
免疫系统
生物杀虫素A
生物
免疫学
内科学
大豆黄酮
环境卫生
染料木素
川地34
遗传学
作者
Vinod Kumar Jaina,Abhisheik Chowdary Eedara,Sasi Priya SVS,Surender Singh Jadav,Sabarinadh Chilaka,Ramakrishna Sistla,Sai Balaji Andugulapati
标识
DOI:10.1016/j.procbio.2022.10.029
摘要
Multiple myeloma (MM) is a malignant neoplasm of B-cells characterised by the uncontrolled proliferation of plasma cells in the bone marrow. Despite the advancements in MM treatment, it has a poor prognosis with a median survival of 3–5 years. CD38 has been one of the key therapeutic targets for MM, due to its high expression in MM cells conferring its role in immune evasion and cancer progression. Therefore, novel compounds targeting CD38 with low toxicity are warranted for improved MM therapy. In this study we aimed to investigate the anticancer activity of Biochanin A (BCA), an isoflavone, against Multiple myeloma. BCA treatment induced apoptosis in MM cells and showed reduced cytokine expression levels. In-addition, BCA significantly reduced the CD38 population and cancer stem-cell markers in dose dependent manner. Consistently, we observed BCA treatment significantly reduced the stemness markers and invasion capability of cells. Furthermore, BCA treatment significantly attenuated the tumour growth in U266 induced tumour model in NOD/SCID mice. Mechanistic studies revealed that BCA anti-cancer activities are exerted by modulating the NF-κB and MAPK signalling pathways. Overall, this study enlightens the application of BCA as a novel treatment modality for multiple myeloma with superior efficacy and reduced toxicity.
科研通智能强力驱动
Strongly Powered by AbleSci AI